Pyridazinoquinolinetriones as NMDA Glycine-Site Antagonists with Oral Antinociceptive Activity in a Model of Neuropathic Pain
Journal of Medicinal Chemistry2007Vol. 50(13), pp. 3113–3131
Citations Over Time
Thomas M. Bare, Dean G. Brown, Carey L. Horchler, Megan Murphy, Rebecca A. Urbanek, Vernon Alford, Christine Barlaam, Martin C. Dyroff, James Empfield, Janet M. Forst, Keith J. Herzog, Richard A. Keith, Alan S. Kirschner, Chi-Ming C. Lee, Joseph J. Lewis, Frances M. McLaren, Kathy L. Neilson, Gary B. Steelman, Shephali Trivedi, Edward P. Vacek, Wenhua Xiao
Abstract
A series of 7-chloro-2,3-dihydro-2-[1-(pyridinyl)alkyl]-pyridazino[4,5-b]quinoline-1,4,10(5H)-triones were synthesized and found to have potent activity at the glycine site of the NMDA receptor. In some cases, these compounds possessed poor aqueous solubility that may have contributed to poor rat oral bioavailability. Subsequently, compounds have been identified with improved aqueous solubility and oral bioavailability. Several of these compounds were examined in a rat chronic constrictive injury (CCI) model of neuropathic pain and found to have potent activity when dosed orally.
Related Papers
- → Neuropathic pain in patients with sickle cell disease(2013)112 cited
- → MiR-183-5p Alleviates Chronic Constriction Injury-Induced Neuropathic Pain Through Inhibition of TREK-1(2018)35 cited
- → Silencing of lncRNA PKIA-AS1 Attenuates Spinal Nerve Ligation-Induced Neuropathic Pain Through Epigenetic Downregulation of CDK6 Expression(2019)33 cited
- → Can the Neuropathic Pain Scale Discriminate Between Non-neuropathic and Neuropathic Pain?(2008)45 cited
- → Loss of SNHG4 Attenuated Spinal Nerve Ligation-Triggered Neuropathic Pain through Sponging miR-423-5p(2020)17 cited